American Century Companies Inc. Purchases 770,198 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

American Century Companies Inc. increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 43.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,528,186 shares of the biopharmaceutical company’s stock after buying an additional 770,198 shares during the quarter. American Century Companies Inc. owned 2.06% of Catalyst Pharmaceuticals worth $49,805,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Royal Bank of Canada raised its stake in shares of Catalyst Pharmaceuticals by 39.1% during the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock worth $5,177,000 after acquiring an additional 60,040 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Catalyst Pharmaceuticals by 5.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock valued at $1,749,000 after purchasing an additional 3,800 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Catalyst Pharmaceuticals by 11.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after purchasing an additional 333,100 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Catalyst Pharmaceuticals by 99.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock worth $12,763,000 after purchasing an additional 262,392 shares during the last quarter. Finally, Intech Investment Management LLC lifted its stake in Catalyst Pharmaceuticals by 6.5% in the first quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock worth $1,700,000 after purchasing an additional 4,261 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Down 1.5%

NASDAQ:CPRX opened at $24.32 on Friday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $26.58. The company has a 50-day moving average price of $23.86 and a 200-day moving average price of $22.32. The stock has a market cap of $2.97 billion, a price-to-earnings ratio of 14.39, a P/E/G ratio of 0.73 and a beta of 0.75.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Citigroup raised their price objective on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday. Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Wall Street Zen raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, November 16th. Oppenheimer reissued an “outperform” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 7th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $34.00.

Key Catalyst Pharmaceuticals News

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Zacks upgraded CPRX to a Rank #1 (Strong Buy), and the firm has featured the stock on its recent momentum and value lists — a catalyst for buy-side interest and potential inflows. All You Need to Know About Catalyst (CPRX) Rating Upgrade to Strong Buy Best Momentum Stock to Buy for March 4th
• Positive Sentiment: Citigroup raised its price target on CPRX to $35 — a notable upward revision that can support mid‑term upside from institutional or model-driven buying. Citigroup Raises Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target to $35.00
• Neutral Sentiment: Short-interest reports flagged a “large increase,” but the underlying data shows 0 shares and NaN changes — indicating a reporting/data error rather than demonstrated ramp in short bets. Investors should treat the short-interest headline as unreliable until corrected by the data provider.
• Neutral Sentiment: Trading activity is above average (volume higher than its 3‑month average) and the shares sit nearer the 52‑week high; that combination can amplify intraday volatility and lead to profit‑taking even amid positive analyst actions.

Insider Activity at Catalyst Pharmaceuticals

In other news, Director Molly Harper sold 26,746 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $23.25, for a total value of $621,844.50. Following the transaction, the director owned 2,360 shares in the company, valued at approximately $54,870. This represents a 91.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 10.40% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).